Mangoceuticals Signs Deal with BarStool Sports to Market Mango on Popular “Only Stans” Podcast
08 juin 2023 09h00 HE
|
Mangoceuticals, Inc.
Dallas, Texas, June 08, 2023 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ:MGRX) (“MangoRx” or the “Company”), a company focused on developing, marketing and selling a variety of men’s health and...
Erectile Dysfunction Drugs Market to Reach $5.1 Billion, Globally, by 2032 at 6.5% CAGR: Allied Market Research
11 mai 2023 10h13 HE
|
Allied Market Research
Portland, OR, May 11, 2023 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, “Erectile Dysfunction Drugs Market By Product (Sildenafil, Avanfil, Tadalafil, Udenafil, and...
Over 20 Million Suffer From Peripheral Neuropathy, St. Pete Medical Group Aims to Help
14 déc. 2022 12h30 HE
|
St. Pete Medical Group
ST. PETERSBURG, Fla., Dec. 14, 2022 (GLOBE NEWSWIRE) -- St. Pete Medical Group and Clearwater Medical Group were featured on 10 Tampa Bay's Great Day Live. Dr. Alex Spinoso announced their mission...
Zylö Receives $263,000 NIH Phase I Grant to Develop a Topical Viagra® for ED
16 sept. 2022 08h30 HE
|
Zylö Therapeutics
Funds to be used to optimize a formulation and demonstrate comparable efficacy to oral Viagra GREENVILLE, SC, Sept. 16, 2022 (GLOBE NEWSWIRE) -- Zylö Therapeutics Inc., developer of the Z-pod®...
Oncotelic Presenting Data for OT101 Against Diffuse Intrinsic Pontine Glioma (DIPG) at the 2022 Society for Neuro-Oncology (SNO) Annual Meeting
14 sept. 2022 08h15 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), developer of treatments for rare and orphan indications, including...
ONCOTELIC ACQUIRES FAST TO MARKET LATE-STAGE DRUG CANDIDATE FOR PARKINSON DISEASE, ERECTILE DYSFUNCTION, AND FEMALE SEXUAL DYSFUNCTION.
04 oct. 2021 07h00 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC), executed an exclusive licensing agreement on September 30, 2021,...
ONCOTELIC TO ACQUIRE LATE-STAGE DRUG CANDIDATE FOR PARKINSON DISEASE, ERECTILE DYSFUNCTION, AND FEMALE SEXUAL DYSFUNCTION.
01 sept. 2021 12h00 HE
|
Oncotelic Therapeutics, Inc.
AGOURA HILLS, Calif., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. ("Oncotelic" or the "Company") (OTCQB:OTLC), executed a binding term sheet with Autotelic Inc. to license AL-101...
Zylö Receives $1,700,000 NIH Phase II Grant to Advance Erectile Dysfunction Program into Human Trials
20 juil. 2021 09h00 HE
|
Zylö Therapeutics
Funds to be used for scale-up, implementation of cGMP quality system, and pre-IND FDA meeting GREENVILLE, SC, July 20, 2021 (GLOBE NEWSWIRE) -- Zylö Therapeutics Inc., developer of the...
US Erectile Dysfunction Market and Competitive Landscape Report 2021: Epidemiology, Key Products Marketed, Market Valuations and Forecast, Drugs Sales and Market Shares
08 juin 2021 04h58 HE
|
Research and Markets
Dublin, June 08, 2021 (GLOBE NEWSWIRE) -- The "US Erectile Dysfunction Market and Competitive Landscape - 2021" report has been added to ResearchAndMarkets.com's offering. US Erectile Dysfunction...
Leonhardt Ventures LLC Announces Plans To Take Bids for MyoStim ED ErectiStim TM Erectile Dysfunction IP and Assets
02 juin 2021 11h32 HE
|
Leonhardt Ventures LLC
United States, California, Newport Beach, June 02, 2021 (GLOBE NEWSWIRE) -- -- Leonhardt Ventures LLC and it's innovation accelerator subsidiary Leonhardt's Launchpads by Cal-X Stars...